Moderna Says Vaccine Could Have Long Term Immunity
On Thursday, Moderna Inc. stated that its COVID-19 vaccine has long-term immunity potential, according to MarketWatch.
Furthermore, the company expects to have 20 million doses of its vaccine in the US by the end of the year. According to a study from the National Institute of Allergy and Infectious Diseases, participants in the clinical vaccine trial retained “high levels of neutralizing antibodies” for three months following the first vaccination. The vaccine has “the potential to provide durable” immunity, with no serious side effects.
“These interim Phase 1 data suggests that mRNA-1273, our COVID-19 vaccine candidate, can generate durable neutralizing antibodies across all age groups including in older and elderly adults,” Moderna said. The company also said it expected to have between 100 and 125 million doses available globally by the first quarter of 2021. 85 to 100 million of these vaccines will be available in the US.